Document is current

Any future updates will be listed below

Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up

Crossref DOI link: https://doi.org/10.1007/s13760-024-02572-3

Published Online: 2024-05-20

Published Print: 2024-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark